Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-07 02:01 UTC

BIOMED PULSE

September 7, 2026 - Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now spread to 60 health zones across six provinces, making it the largest Ebola outbreak ever recorded in DRC history. [1] Alongside active Ebola spread, the aging science front is grappling with how heat stress, testosterone trade-offs, and cellular senescence are quietly shaping how long we live — today's overall mood: urgent on pathogens, cautiously optimistic on longevity biology. [2] [3]

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) - DRC AND UGANDA

  • As of August 28, 2026, the Bundibugyo virus disease (BVD) outbreak has spread from 54 to 60 health zones across six DRC provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo. [1]
  • WHO characterizes the DRC outbreak as the largest Ebola outbreak ever reported in the country, marked by sustained transmission and faster geographic expansion than any prior Ebola outbreak. [2]
  • As of July 15, 2026, the cumulative DRC toll stood at 2,124 confirmed cases including 828 deaths, with cross-border transmission to Uganda still ongoing. [4]
  • The outbreak originated in Mongbwalu Health Zone, Ituri Province, first flagged to WHO on May 5, 2026; the Institut national de recherche biomédicale (INRB) confirmed Bundibugyo virus on May 14. [5]
  • CDC mobilized an international Ebola response beginning May 17, 2026, and enhanced airport screening was activated at Washington-Dulles and then expanded to Atlanta's Hartsfield-Jackson airport. [6] [7]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • WHO's fifth Disease Outbreak News on this cluster confirms the pathogen as Andes hantavirus (ANDV), originating from severe acute respiratory illness cases aboard cruise ship M/V Hondius, first notified to WHO on May 2, 2026. [8]
  • The initial cluster involved 7 cases (2 laboratory-confirmed, 5 suspected) among the ship's 147 passengers and crew as of the first May 4 report; subsequent updates confirmed additional cases across multiple countries. [9] [10]
  • CDC issued multiple response transcripts from May through June 24, 2026, and confirmed the public risk to Americans remains extremely low.

NIPAH VIRUS - INDIA

  • On June 11, 2026, Kerala State Health Department confirmed a laboratory case of Nipah virus (NiV) infection in an adult male in Kozhikode district; the patient developed neurological symptoms, with illness onset May 30 and hospitalization June 10.

AVIAN INFLUENZA A(H9N2) - ITALY

  • Italy notified WHO on March 21, 2026, of a human H9N2 case in an adult male who had returned from Senegal; next-generation sequencing confirmed Influenza A(H9N2).

MEASLES - BANGLADESH

  • Bangladesh reported a nationwide measles surge affecting 58 of 64 districts across all eight divisions, with 19,161 suspected cases and 2,897 laboratory-confirmed cases as of the April 4, 2026 notification to WHO.

YELLOW FEVER - GLOBAL

  • WHO reported that from January 1 to May 26, 2026, six countries reported a total of 79 human yellow fever infections, with transmission activity persisting into 2026 following a surge in the Americas in 2025.

SALMONELLA - METABOLIC MEALS HOME DELIVERY

  • CDC flagged an active Salmonella outbreak on September 5, 2026, linking 16 illnesses in 10 states to certain Metabolic Meals home delivery food products.

DRUG-RESISTANT BACTERIA - NATIONAL ALERT

  • A recent CDC report found a dramatic and sharp rise in dangerous drug-resistant bacteria nationwide, underscoring continued antimicrobial resistance as a growing public health threat.

🧬 LONGEVITY & AGING

TESTOSTERONE: A LONGEVITY-FERTILITY TRADE-OFF

  • A Mendelian randomization study published in Aging Male (authors Jiesisibieke ZL and Schooling CM, August 2026) used genetic data to investigate whether testosterone confers survival benefits or trades them off against reproductive fitness — with implications for hormonal aging therapies. [3]
  • An international expert consensus published in Aging Male (August 26, 2026) by Hackett, Jones, Khera, Traish, Zitzmann, Morgentaler and colleagues addresses managing testosterone deficiency in primary care, relevant to the aging male population whose androgen levels decline with age.

CELLULAR SENESCENCE AND INTERVERTEBRAL DISC DEGENERATION

  • A Biomaterials study (Shi P et al., July 14, 2026) engineered senescence-targeting apoptotic extracellular vesicles loaded into injectable hydrogel microspheres to reduce ferroptosis in nucleus pulposus cells, slowing intervertebral disc degeneration — a common painful condition of aging spines.

SENESCENCE CYCLE IN OSTEOARTHRITIS

  • An An X et al. study in Bioactive Materials (July 31, 2026) demonstrated that combining antioxidant and epigenetic synergy can interrupt the self-perpetuating senescence cycle in osteoarthritis cartilage cells, potentially opening new treatment pathways for a leading cause of age-related disability.

EGFR LOSS AND IMPAIRED FRACTURE HEALING IN AGED MICE

  • Research in Bioactive Materials (Hu Y et al., August 4, 2026) found that loss of EGFR (epidermal growth factor receptor) activity in skeletal stem and progenitor cells is associated with the well-known impaired fracture healing seen in aged mice — pinpointing a cellular mechanism behind the poorer bone repair of older patients.

ABCA1 AND AGE-RELATED BONE DEFECTS

  • A dual-targeting mRNA lipid nanoparticle that restores ABCA1-dependent cholesterol homeostasis was shown by Cheng M et al. in Bioactive Materials (August 20, 2026) to promote repair of age-related bone defects, combining mRNA delivery technology with geroscience bone biology.

HEAT STRESS AND THE AGING WORLD

  • A Lancet Planetary Health global projection study (Kong Q, Vecellio DJ, Huber M et al.) modeled how exceeding human heat tolerance will disproportionately affect an aging global population in a warming climate, flagging older adults as the highest-risk group for physiological heat failure.

DEPRESCRIBING IN OLDER PATIENTS

  • Two Lancet Healthy Longevity commentaries (Hwang CS, Boockvar KS, Steinman MA; and Van der Linden LR) argue that deprescribing trials for older patients must adopt a rationale-first framework before choosing study design — critical for reducing polypharmacy harm in the elderly.

HIP FRACTURE SURGERY AND ANAESTHESIA IN OLDER PATIENTS

  • A multicentre randomised clinical trial from Germany published in Lancet Healthy Longevity (Kowark A et al., August 7, 2027 online ahead) compared spinal versus general anaesthesia for serious complications in older hip fracture surgery patients across multiple German centres.

METFORMIN DELIVERY FOR OSTEOARTHRITIS

  • A study in Biomaterials (Han Q et al., July 6, 2026) engineered a chondrocyte-targeting tetrahedral DNA-based nanoparticle to deliver metformin — the widely studied longevity-associated drug — directly to joint cartilage cells, improving outcomes in an osteoarthritis model.

DEMENTIA AND CANCER INCIDENCE: SEX-SPECIFIC ECOLOGY

  • You W, Chang HR, Henneberg M et al. published in Future Science OA (September 4, 2026) a sex-specific ecological analysis across countries examining the relationship between dementia incidence and cancer incidence rates — part of ongoing research into the biology shared by aging, neurodegeneration, and malignancy.

💊 NEW CURES & APPROVALS

  • KRAZATI (adagrasib), sponsor Bristol-Myers Squibb, received a supplemental approval (SUPPL AP) via NDA216340, targeting KRAS-mutant cancers; adagrasib is a KRAS G12C inhibitor relevant to lung and other solid tumors.
  • CIBINQO (abrocitinib), sponsor Pfizer, received a supplemental approval via NDA213871; abrocitinib is a JAK1 inhibitor indicated for moderate-to-severe atopic dermatitis.
  • FYARRO (sirolimus), sponsor AADI, received a supplemental approval via NDA213312; sirolimus (rapamycin) is an mTOR inhibitor indicated for malignant perivascular epithelioid cell tumors (PEComa) — and is of significant interest in longevity research due to mTOR's role in aging pathways.
  • BYOOVIZ (ranibizumab-nuna), sponsor Samsung Bioepis, received a supplemental approval via BLA761202; it is a biosimilar to Lucentis indicated for neovascular age-related macular degeneration and other retinal conditions affecting older adults.
  • SHEUR (elagolix / estradiol / norethindrone acetate combination), sponsor Teva Pharmaceuticals, received an original tentative approval (ORIG TA) via ANDA217650, a hormonal product combining GnRH antagonist elagolix with add-back estradiol and norethindrone acetate for endometriosis-associated pain management.
  • DAPAGLIFLOZIN (generic), sponsor Ajanta Pharma, received a supplemental approval via ANDA211482; dapagliflozin is an SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease — drug classes actively studied for longevity and cardiometabolic benefits.
  • NEVIRAPINE (generic), sponsor Mylan, received a supplemental approval via ANDA205651; nevirapine is a non-nucleoside reverse transcriptase inhibitor used in HIV treatment.

🧪 CLINICAL TRIALS

UROLITHIN A FOR GLUCOSE METABOLISM IN ADULTS 55+ (NCT06274749)

  • A randomized, triple-masked, controlled trial is studying whether Urolithin A (UA) supplementation — a natural gut microbiome-derived compound that activates mitophagy — improves glucose metabolism in healthy adults aged 55 years and older, targeting the age-related decline in pancreatic insulin secretion.

NICOTINAMIDE RIBOSIDE FOR FATTY LIVER DISEASE (NCT06044935)

  • A NIH trial is testing nicotinamide riboside (NR), an NAD+ precursor supplement, combined with a low-carbohydrate diet for metabolic rate and fat oxidation in adults with fatty liver disease; at least 30% of Americans are affected by non-alcoholic fatty liver, which worsens with age.

KARXT FOR ALZHEIMER'S DISEASE PSYCHOSIS - ADEPT-2 (NCT06126224)

  • This Phase 3 randomized, double-blind, placebo-controlled trial evaluates KarXT (xanomeline-trospium, a dual muscarinic receptor agonist) for psychosis associated with Alzheimer's disease in patients aged 55 to 90; the primary endpoint is reduction of moderate-to-severe AD-related psychosis.

VENETOCLAX PLUS ASTX727 IN ELDERLY AML PATIENTS (NCT04746235)

  • A Phase II trial updated September 4, 2026 studies the BCL-2 inhibitor venetoclax combined with ASTX727 (cedazuridine/decitabine) in elderly, newly diagnosed AML patients not eligible for intensive chemotherapy, a population where standard intensive regimens carry prohibitive toxicity.

FOSTAMATINIB IN LUNG TRANSPLANT PATIENTS - SIMILAR TRIAL (NCT06948097)

  • The SIMILAR trial is evaluating the Syk kinase inhibitor fostamatinib for safety and tolerability in lung transplant patients who develop donor-specific antibodies (DSA), which drive antibody-mediated rejection and limit post-transplant survival beyond 6 to 7 years.

TILREKIMIG FOR MODERATE-TO-SEVERE ECZEMA (NCT07765888)

  • A trial registered September 4, 2026 is studying tilrekimig (an investigational biologic) combined with topical corticosteroids in adults and adolescents with moderate-to-severe atopic dermatitis, assessing efficacy, safety, and pharmacodynamics.

📢 PUBLIC HEALTH

KINDERGARTEN VACCINATION RATES

  • CDC data released August 17, 2026 show kindergarten vaccination rates remain high overall, though a slight 0.1% decline in coverage was noted — a signal authorities are watching given the ongoing national measles situation.

WEST NILE VIRUS - RECORD EARLY SEASON

  • CDC warned on July 1, 2026 of a record early West Nile virus season, urging Americans to prevent mosquito bites especially during warm weather and outdoor gatherings; repellents and eliminating standing water remain the primary tools.

CYCLOSPORA OUTBREAK - TACO BELL LETTUCE (RESOLVED SOURCE)

  • As of July 17, 2026, shredded iceberg lettuce served at Taco Bell locations was confirmed as the source of Cyclospora infections in five states, with 1,644 people sickened; the outbreak has since expanded to additional states.

SALMONELLA - ALFALFA SPROUTS DUAL OUTBREAK

  • CDC warned August 21, 2026 of a multistate outbreak involving both Salmonella and E. coli linked to a recalled alfalfa sprout product — an unusual dual-pathogen food safety event.

SYPHILIS IN NEWBORNS RISES FOR 12TH CONSECUTIVE YEAR

  • New CDC data released September 24, 2025 showed U.S. congenital syphilis cases increased for the 12th consecutive year in 2024, a persistent public health failure in prenatal STI screening and treatment.

E. COLI - FROZEN BLUEBERRIES

  • CDC warned on July 7, 2026 of an E. coli outbreak linked to frozen blueberries, with a product recall in effect; consumers should not eat the recalled product.

THIS BRIEFING IS INFORMATIONAL ONLY AND DOES NOT CONSTITUTE MEDICAL ADVICE.

Sources: CDC Newsroom, WHO Disease Outbreak News, openFDA Drugs@FDA, ClinicalTrials.gov, Europe PMC / PubMed.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Mendelian randomization investigation into testosterone's trad… — Europe PMC — Longevity
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  7. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  8. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  9. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News
  10. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260907-02-v68 · 2026-09-07 02:01 UTC · pulse.uzylab.com

Read next